About Crossject
Crossject is revolutionizing the administration of well-established, clinically-proven treatments and bringing unprecedented advantages to patients with its innovative, needle-free auto-injector ZENEO®.
ZENEO® is no less than 12 years of R&D and more than 400 obtained patents.
Currently, 8 treatments are in advanced stages of development, which 7 for emergency situations.
With its unique know-how, Crossject aims to become a world leader in the self-administration of emergency needle free injectables.
Listed on the Alternext (Euronext Paris) market since February 2014, the company has completed three fund raising campaigns and furthermore received financing from the French Ministry of Defense and grants from Bpifrance as part of the Investissements d'Avenir program.
|
|
|
51-200 employees
View all Crossject employees
|
|
Pharmaceutical Manufacturing
|
|
6-8 rue Pauline Kergomard,Dijon,Bourgogne,FR
|
|
2001
|
|
Injection Sans Aiguile And Traitements D'urgence
|
Crossject Alternatives
Search Crossject Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
